睿知中国医院研究地图
候选清单

正在招募肺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 41 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 41

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心新疆医科大学附属肿瘤医院Affiliated Cancer Hospital of Xinjiang Medical University乌鲁木齐医院页面
  2. 研究中心广东医科大学附属医院Affiliated Hospital of Guangdong Medical University湛江医院页面
  3. 研究中心河北大学附属医院Affiliated Hospital of Hebei University石家庄医院页面
  4. 研究中心内蒙古医科大学附属医院Affiliated Hospital of Inner Mongolia Medical University呼和浩特医院页面
  5. 研究中心安徽省胸科医院Anhui Chest Hospital合肥医院页面
  6. 研究中心首都医科大学附属北京胸科医院Beijing Chest Hospital北京医院页面
  7. 研究中心山东第一医科大学附属中心医院(济南市中心医院)Central Hospital Affiliated to Shandong First Medical University济南医院页面
  8. 研究中心重庆医科大学附属第一医院First Affiliated Hospital of Chongqing Medical University重庆医院页面
  9. 研究中心广州医科大学附属第一医院First Affiliated Hospital of Guangzhou Medical University广州医院页面
  10. 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
  11. 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
  12. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  13. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  14. 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
  15. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  16. 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
  17. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  18. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  19. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  20. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  21. 研究中心吉林省肿瘤医院Jilin Cancer Hospital长春医院页面
  22. 研究中心LinYi Cancer Hospital临沂医院页面
  23. 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
  24. 研究中心南通市肿瘤医院Nantong Tumor Hospital南通医院页面
  25. 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
  26. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  27. 研究中心南昌大学第二附属医院Second Affiliated Hospital of Nanchang University南昌医院页面
  28. 研究中心大连医科大学附属第二医院Second Hospital of Dalian Medical University大连医院页面
  29. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  30. 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面
  31. 研究中心汕头大学医学院附属医院Shantou University Medical College hospitals汕头医院页面
  32. 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
  33. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  34. 研究中心温州医科大学附属台州医院Taizhou Hospital, Wenzhou Medical University台州医院页面
  35. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  36. 研究中心天津医科大学总医院Tianjin Medical University General Hospital天津医院页面
  37. 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
  38. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  39. 研究中心四川大学华西医院West China Hospital成都医院页面
  40. 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面
  41. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT04928846,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. A histologically or cytologically documented non-squamous cell NSCLC that is locally advanced or metastatic.

    入选标准第 5 条

  3. Have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting.

    入选标准第 10 条

    Have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC

    入选标准第 11 条

    Unresolved nor adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.

    排除标准第 12 条

  4. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.

    入选标准第 9 条

  5. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    入选标准第 8 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT04928846,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Projected life expectancy of at least 12 weeks.
  2. Participants must have c-Met overexpressing non-small cell lung cancer (NSCLC) as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory using the VENTANA MET (SP44) RxDx assay.
  3. Archival or fresh tumor material must be submitted for assessment of c-Met protein expression levels during the Pre-Screening period. Tumor material from the primary tumor site and/or metastatic sites are allowed.
  4. If a participant was prescreened for Study M14-239 but did not enroll, tumor material previously submitted for Study M14-239 may be used for Study M18-868 Pre-Screening upon confirmation from AbbVie that sufficient evaluable tumor material is available (Except China).
  5. A histologically or cytologically documented non-squamous cell NSCLC that is locally advanced or metastatic.
  6. A known epidermal growth factor receptor (EGFR) activating mutation status.
  7. Actionable alterations in genes other than EGFR are eligible.
  8. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  9. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
  10. Have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting.
  11. Have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC
  12. Participants WITHOUT an actionable gene alteration: must have progressed on (or be considered ineligible for) platinum-based chemotherapy and immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy).
  13. Participants WITH an actionable gene alteration for which immune checkpoint inhibitor therapy is not standard of care (e.g., anaplastic lymphoma kinase [ALK] translocation): must have progressed on (or be considered ineligible for) anti-cancer therapy targeting driver gene alterations and platinum-based chemotherapy.
  14. Participants with gene alterations for which immune checkpoint inhibitor is standard of care must have also progressed on (or be considered ineligible for) immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy).
  15. Must be considered appropriate for docetaxel therapy based on the assessment of the treating physician.
  16. Participants with metastases to the central nervous system (CNS) are eligible only after adequate treatment (such as surgery, radiotherapy, or drug therapy) is provided and:
  17. They are asymptomatic and off or on a stable or reducing dose of systemic steroids (on no more than 10 mg per day [QD] prednisone or equivalent) and/or anticonvulsants for at least 2 weeks prior to randomization.

排除标准:Exclusion Criteria:

  1. Evidence of new, untreated CNS metastases or progressing CNS metastases after treatment.
  2. Evidence of leptomeningeal disease.
  3. Participants with adenosquamous or neuroendocrine histology, nor sarcomatoid features.
  4. Epidermal growth factor receptor (EGFR) activating mutations.
  5. Participants who have received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E..
  6. Participants who have received prior docetaxel therapy.
  7. A history of other malignancies except:
  8. Malignancy treated with curative intent and with no known active disease present for >=2 years before the first dose of study drug and felt to be at low risk for recurrence by investigator. Additionally, participants must not be receiving any ongoing anti-cancer therapy, including maintenance therapy, prior to randomization..
  9. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
  10. Adequately treated carcinoma in situ without current evidence of disease.
  11. A history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, evidence of active pneumonitis on screening chest computed tomography (CT) scan or prior pneumonectomy. A history of prior radiation pneumonitis in the radiation field (fibrosis) is not permitted.
  12. Unresolved nor adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
  13. Major surgery within 21 days prior to randomization.
  14. Clinically significant condition(s) as listed in the protocol.

引自 ClinicalTrials.gov, NCT04928846, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT04928846,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT04928846